A clinical trial was conducted to evaluate the efficacy of a newly developed monoclonal antibody (mAb-42) designed to target and neutralize a spike protein on a viral pathogen. Table 1 shows the percentage of viral cultures showing a greater than 90% reduction in viral load across four different dosage levels, compared to a standard antiviral drug control group.
| Dosage of mAb-42 (mg/kg\text{mg/kg}mg/kg) | Cultures showing >90% reduction with mAb-42 (%) | Cultures showing >90% reduction with standard control (%) |
|---|---|---|
| 1.5 | 14.8 | 12.5 |
| 3.0 | 32.4 | 28.6 |
| 6.0 | 65.2 | 58.1 |
| 12.0 | 91.5 | 84.0 |
At a dosage of 1.5 mg/kg, 7,815 cultures treated with the monoclonal antibody mAb-42 showed a greater than 90% reduction in viral load.
Calculate the total number of viral cultures treated with mAb-42 at this dosage in this clinical trial.
Give your answer to 4 significant figures.
